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ABBREVIATIONS 
 
5’UTR – 5’Untranslated Region 
AD – Autosomal-Dominant 
AR – Autosomal-Recessive 
BMD – Bone Mineral Density  
BMP – Bone Morphogenetic Protein 
BRIL – Bone-Restricted Ifitm-Like Protein 
BS – Bruck Syndrome 
CCDS – Consensus Coding Sequence 
cDNA – Complementary DNA 
CNV – Copy Number Variation 
COMP – Cartilage Oligomeric Matrix Protein 
CRTAP – Cartilage-Associated Protein 
CyPB – Cyclophilin B 
DI – Dentinogenesis Imperfecta 
ECM – Extracellular Matrix 
EDS – Ehlers-Danlos Syndrome 
ER – Endoplasmatic Reticulum 
FKBP65 - 65 kDa FK506 Binding Protein 10 
gDNA – Genomic DNA 
HSP47 – Heat Shock Protein 47 
IGV - Integrative Genomics Viewer 
Indel – Insertion-Delition mutation 
LH2 – Lysyl Hydroxylase 2 
LRP5 – Lipoprotein Receptor-Related Protein 5 
MAF – Minor Allele Frequency 
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M-CSF – Macrophage Colony Stimulation Factor  
MLBR – Major Ligand Binding Region 
MMP – Matrix Metalloproteinase  
MSC – Mesenchymal Stem Cell 
NCP - Non-Collagen Proteins 
NGS – Next Generation Sequencing 
NMD – mRNA Nonsense Mediated Decay 
OI – Osteogenesis Imperfecta 
OPG – Osteoprotegerin 
OSX – Osterix 
P3H1 – Prolyl 3-Hydroxylase 1 
PEDF – Pigment Epithelium-Derived Factor 
PG – Peptidoglycan  
PPIase – Peptidyl-Prolyl Isomerase 
PTC – Premature Termination 
RANKL – Receptor Activator of NF-κβ Ligand 
rER – Rough Endoplasmatic Reticulum 
RUNX2 – Run-related Transcription Factor 2 
SNP – Single Nucleotide Polymorphism 
SPARC – Secreted Proteins Acidic Rich in Cysteine  
TNFα – Tumor Necrosis Factor-α 
TRIC – Monovalent Cation-Specific Transmembrane Channel 
WGS – Whole Genome Sequencing 
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INTRODUCTION  
Osteogenesis Imperfecta is a rare Mendelian disorder, characterized by fragility of the bone 
tissue. The expressivity of the disease is very wide, varying from mild forms, when patients may 
not even know about running cases of the disorder in their family, to severe lethal forms, which 
include extreme fragility and skeletal deformations. The current classification of Osteogenesis 
Imperfecta remains ambiguous, since a lot of cases are boundary and individual. Patients often 
develop different sets of phenotypic manifestations even within one family. Some cases of the 
disease overlap with other disorders of connective tissues.  
Genetic background of Osteogenesis Imperfecta is also diverse. For now, 16 different genes are 
discovered to be involved into pathogenesis of the disease. Mostly genes are connected 
functionally to bone development and homeostasis. However, a few genes of unexpected 
function for bone tissue were described as Osteogenesis Imperfecta causing.  
Generally, OI-causing mutations occur in collagen type I genes. Depending on the type of 
mutation and its position, patients with mutations in the same collagen type I gene may develop 
all ranges of phenotypes, starting from mild forms to lethal forms. As more information from 
Osteogenesis Imperfecta studies becomes available, genotype-phenotype correlations become 
more confusing since people with the same genotypes reveal diverse phenotypes and vice versa. 
Osteogenesis Imperfecta patients have a poor quality of life since no effective treatment exists so 
far. Collecting information about genetic and phenotypic diversity may help understand 
genotype-phenotype correlations and molecular mechanisms related to pathogenicity of the 
disease and lead to the development of efficient treatment.  
The main aim of this thesis is to give an overview of Osteogenesis Imperfecta phenotypic, 
genetic and molecular background. In the experimental part of the study exome analysis of three 
Estonian OI families is performed in order to identify the disease causing mutations. 
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1. LITERATURE REVIEW 
 
1.1  Osteogenesis Imperfecta review 
Osteogenesis Imperfecta (OI) is a group of heterogeneous genetic disorders, known also as a 
„brittle bone disease“, Vrolik syndrome or Lobstein syndrome. The prevalence of OI ranges 
about 1 per 20,000 to 30,000 births
1
 according to OI type being considered (Byers et al., 1992; 
Steiner et al., 1993; Sillence et al., 1979). The estimated number of OI families in Estonia is 32.   
OI is a disorder of connective tissue matrix. The hallmark of the condition lays in bone fragility 
and easy fractures, caused by decreased bone mass (Kocher and Shapiro, 1998). No deviations of 
D3 vitamin, osteocalcin and parathyroid hormone levels were identified in OI patients (Mörike et 
al., 1993; Palomo et al., 2014). Patients may develop secondary clinical features, such as a short 
stature, Dentinogenesis Imperfecta (DI), osteoporosis, scoliosis, joint laxity, blue or grayish eye 
sclera, progressive hearing loss, easy bruising, skeletal deformity, Wormian bones and skull 
sutures. The range of affection is spread from mild osteopenia to moderate and severe forms, 
which include limb deformity and lethal cases (Roughley et al., 2003). Sillence classification 
differentiates four basic classical types of OI, by severity. Recently the fifth type was added to 
traditional classification. In addition to genetic predisposition, environment (climate, physical 
activity, diet, treatment) may influence the phenotype development of an OI patient (Roughley et 
al., 2003). 
Genetics of this disorder is extremely heterogeneous. The pattern of inheritance can be 
autosomal-dominant (AD), as well as autosomal-recessive (AR). More than 1,000 mutations in 
16 different genes are already known to cause Osteogenesis Imperfecta.
2
 On the basis of the 
affected genes, genetic OI classification differentiates 15 OI types.  
Molecular pathology of OI is based on qualitative or quantitative defects of type I collagen. 
About 85-90% of OI cases are caused by dominant mutations in  COL1A1 and COL1A2 genes, 
encoding for collagen I proα1 and proα2 polypeptide chains respectively (Byers and Pyott, 
2012), and IFITM5 gene (Lazarus et al., 2014). The rest - 10-15% of OI cases represent 
_______________________ 
1 
http://www.orpha.net/  
2
https://oi.gene.le.ac.uk/home.php    25/05/2014 
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recessive forms of the disorder. Recessive OI is caused by the defects in genes, connected with 
collagen type I post-translational modifications (CRTAP, LEPRE1, PPIB, PLOD2), folding and 
transport (SERPINH1, FKBP10), osteoblasts gene transcription and proliferation (OSX, 
CREB3L1), and mineralization (SERPINF1) or cell signaling (WNT1, TMEM38B). However, 
some cases of AR-OI with mutations in COL1A1 and COL1A2 genes are also known (Forlino et 
al., 2011; Glorieux and Moffatt, 2013). 
 
1.2 Bone biology  
Bones are endoskeleton organs of vertebrates, composed of dense connective osseous tissue. 
Adult human skeleton consists of 206 bones which accomplish a number of mechanic, synthetic 
and metabolic functions (Steele et al., 1988). Bones act as an endocrine organ, store minerals, 
release growth factors and hormones, and provide hematopoiesis (Lee et al., 2007). Bones 
provide movement of muscles, protect internal organs, support the body, take part in sound 
transduction, and are extremely important in functioning of the whole human body (Currey, 
2002).  
 
1.2.1  Cellular structure of bone tissue  
Osseous tissue is a mineralized dynamic structure, composed of organic and non-organic parts. 
Bone mineral residues increase bone strength. Organic part of the bone supplies it with elasticity 
(Clarke et al., 2008). Bone is constantly reorganized by osteoblasts, which produce matrix and 
mineral parts, and osteoclasts, which participate in bone resorption (Figure 1) (Clarke et al., 
2008).  
Osteoblasts synthesize type I collagen and mineralize it by saturating intracellular matrix with 
calcium and phosphate ions in the form of hydroxyapatite Ca10(PO4)6(OH)2. Osteoblasts also 
secrete non-collagen proteins (NCP), hormones and enzymes which effect osteogenesis 
(Buckwalter et al., 1996). Osteoblasts are differentiated from mesenchymal stem cell’s (MSCs) 
under the regulation of pigment epithelium-derived factor (PEDF), Osterix (OSX), run-related 
transcription factor 2 (RUNX2) and SOX9 transcription factor (Long, 2012). Osteoblast 
differentiation is promoted by WNT and bone morphogenetic protein (BMP) signaling pathways 
(Lin and Hankenson, 2011).  
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Trapped in dense bone tissue, osteoblasts differentiate into osteocytes and gain regulatory 
function towards osteoblasts and osteoclasts, which are derived from monocyte-macrophages 
precursors (Buck and Dumanian, 2012). Osteocytes control oxygen and mineral levels in bones 
(Figure 1) (Currey 2012, Noble 2008). They are able to influence bone formation indirectly with 
parathyroid hormone or modulate bone mass by canonical WNT-β-catenin signaling pathway 
(Cui et al., 2011; Clarke et al., 2008). 
 
 
 
 
 
 
 
Figure 1 Bone cells: osteocyte, osteoblast, osteogenic stem cell, osteoclast (Betts et al., 2013). 
 
Osteoclasts are large multinuclear cells with phagocytic-like activity against mineral and organic 
components of the bone (Figure 1). Cells of osteoblastic lineage regulate osteoclastic 
proliferation and resorption processes via macrophage colony stimulation factor (M-CSF), 
receptor activator of NF-κβ ligand (RANKL), tumor necrosis factor-α (TNFα), and 
osteoprotegerin (OPG) (Clarke et al., 2008). 
 
1.2.2  Bone extracellular matrix and matrix mineralization 
Bone extracellular matrix (ECM) is composed of collagen proteins on 85-90% (Miller 1984). 
There are 19 types of collagens which slightly differ by primary structure. Bone, skin, dentin and 
tendon collagen share the same structure and are recognized as type I collagen (Gelse et al., 
2003).  
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Only in vertebrates collagen undergoes transformation, becoming mineralized skeletal structure, 
which defines the main biomechanical properties of the bone. Mineral crystals are connected to 
collagen fibrils by ionic and Van der Waals forces (Currey 2012). Bone collagen fibrillar 
network is enriched by NCP – integrin-binding glycoproteins and proteoglycans – which 
regulate deposition of minerals into ECM (Horton et al., 1995). For example, alkaline 
phosphatase binds to the surface of osteoblasts and increases matrix mineralization (Clarke et al., 
2008).  
 
1.2.3  Collagen type I biosynthesis 
Collagen type I is synthesized in the rough endoplasmatic reticulum (rER) as a procollagen 
heterotrimer. Precursor molecule consists of triple helix – two proα1 and one proα2 peptide 
chains, encoded by COL1A1 and COL1A2 genes respectively.  
The amino acid sequence pattern of collagen is unusually rich with glycine (Gly) and proline 
(Pro). Glycine occupies almost every third position of the peptide chain, which is composed of 
triple amino acid motifs of Gly-X-Y. Preprocollagen is translated from mRNAs on ribosome of 
rER and has signal propeptides at N- and C-terminal ends (Boedtker et al., 1983; Cundy 2012). 
Then, preprocollagen enters rER lumen, where N- and C-terminal signal peptide domains are 
removed by signal peptidase.  
The formed procollagen undergoes hydroxylation of proline and lysine (Lys) residues, in specific 
positions relative to glycine locations. Pro is modified into hydroxyproline by prolyl-4 
hydroxylase and prolyl-3 hydroxylase. Y-position Lys is hydroxylated with lysyl-hydroxylase-1. 
Hydroxylation is extremely important for forming a stable structure with intramolecular cross-
links, responsible for the bone tissue strength (Gelse et al., 2003; Cundy 2012; Currey 2012). 
Glucose and galactose are added by hydroxylysyl glycosyltransferase and hydroxylysyl 
galactosyltransferase to specific hydroxylysine residues. Preprocollagen is enriched with intra-
chain disulfide bonds.  
Heat shock protein 47 (HSP47) binds to N-terminus and acts as a chaperone in order to prevent 
premature triple helix formation (Ishida and Nagata, 2011). Afterwards prepropeptide at C-
terminus is synthesized and molecule is folded into triple γ-helical structure from C-terminus to 
N-terminus. Folding is proceeded only with transpeptide bonds of Pro. Peptidyl-prolyl isomerase 
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(a) 
(b) 
(c) 
(PPIase) changes peptide bond from cis position into trans position where needed.  Then, triple 
collagen chain is formed (Gelse et al., 2003). (Supplementary Figure 1).   
Procollagen is transported into Golgi complex and packed into vesicles for extracellular 
transport. Outside the cell, registration peptides are removed from procollagen chains with 
procollagen peptidase. The processed molecule is called tropocollagen. Tropocollagen assembles 
into fibrils (Supplementary Figure 1). Collagen type I microfibril is composed of five 
overlapping monomers. Monomers overlap by 234 residues, forming 67 nm D-period, which is a 
basic repeat structure of a fibril. Each period consists of a “gap” zone and an “overlap” zone, 
composed by dark and light bands (Figure 2). The fibrils covalently cross-link by lysyl oxidase 
and form collagen type I fibers (Gelse et al., 2003; Last and Reiser, 1984) (Supplementary 
Figure 1). 
 
 
 
 
 
 
 
 
 
 
Figure 2 The structure of collagen type I fibril (a) Procollagen triple helix by electron microscopy with 
C-terminus on the right and N-terminus on the left (b) Collagen fibril model with a one D-period included 
into box region (c) Collagen fibril visualization in electron microscopy and positive-negative staining (Di 
Lullo et al., 2002). 
 
 
  
1.2.3.1 Structural domains of collagen type I α1 and α2 chains 
The collagen fibril “overlap” zone consists of cell interaction and structural domains. Cell 
interaction domain is represented by integrin and peptidoglycan (PG) domain receptors. Binding 
sites for molecules, bridging cell surface and ECM, are also situated in the cell interaction 
domain. Usually ligands bind to a few sites of a fibril, which originate from different monomers, 
composing intramonomer multivalent binding pattern (Sweeney et al., 2008). 
C-terminal side of a collagen monomer is rich in ligand-binding sites. There are three “hotspots” 
of compact distribution of the ligand-binding sites, called major ligand binding regions 
(MLBRs). They are composed by residues 80-200 (MLBR1), 680-830 (MLBR2), and 920-C 
terminus (MLBR3) (Di Lullo et al., 2002). 
Integrin-binding sites are represented by 10 regions on the collagen monomer, one of which is a 
Gly-Phe-Hyp-Gly-Glu-Arg sequence, known as a GFPGER site. The integrin binding is 
important for tissue morphogenesis, ECM assembly, and cell signaling (Sweeney et al., 2008). 
Fibrilogenesis also depends on PG, phosphophoryn, fibronectin, cartilage oligomeric matrix 
protein (COMP) binding sites etc. These proteins provide collagen assembly, arrangement and 
mineralization. Ligand-binding sites influence each other directly, by competition for binding 
proteins on overlapping regions, and indirectly, by interfering other binding sites (Di Lullo et al., 
2002).  
Matrix interaction domain consists of binding sites for structural proteins and regions of fibril’s 
cross-linking. In “gap” regions are situated binding sites for hydroxyapatite. Thus, the domain 
controls mineralization of the tissue (Sweeney et al., 2008) (Supplementary Figure 2). 
 
1.2.4  OI effect on bone structure 
OI effect on bone structure depends on a particular OI causing defect. General tendencies include 
bone fragility and low bone mass phenotype. OI patients reveal the presence of immature woven 
bones with poor lamellar structure, decreased trabecular bone volume, and reduced osteoid 
quantity. If collagen processing enzymes are defective, collagen structure is overmodified, and 
the quantity of normal collagen, expression of NCP and transcription factors may be reduced 
(Sarafova et al., 1998; Gioia et al., 2012). Irregular NCP binding to collagen may cause some 
mineralization defects. When decreased, collagen matrix is combined with increased mineral 
content, and alkaline phosphatase activity in OI patients is increased as well as mineralization 
levels, compared to age-matched controls (Gioia et al., 2012). 
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If extracellular signal transduction is defective, cell differentiation is disrupted by the absence of 
normal feedback signals from collagen protein. The number of osteoclasts and osteoblasts is 
increased (Baron et al., 1983). However, the amount of mature differentiated osteoblasts may 
also be downshifted due to apoptosis, caused by stress responses to defective protein synthesis 
(Lisse et al., 2008) (Figure 3). 
 
 
 
 
 
 
 
Figure 3 Features influenced by dominant (left column) and recessive (right column) forms of OI. In the 
middle are listed the features common for both types of OI (Forlino et al., 2011). 
 
 
1.3  OI classification 
Classification of OI is complicated by heterogeneous phenotypes and variety of the genetic basis 
of molecular pathogenic mechanisms. The range of affection is spread from mild osteopenia to 
moderate and severe forms, which include limb deformity and lethal cases. In reality, the 
disorder represents the continuum of severity. Phenotypic traits can vary within a single type of 
OI interfamilially and even intrafamilially (Basel et al., 2009). Early attempts of OI classification 
were based on the age of fracture occurrence. It included osteogenesis imperfecta congenita, 
with the presence of intrauterine fractures; and osteogenesis imperfecta tarda subclassified into 
gravis and levis forms, with fractures occurred respectively during the first year after birth and 
subsequently (Shapiro et al., 2013).  
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1.3.1  Original Sillence Classification 
In 1979, clinical classification based on skeletal features was proposed by Sillence (Sillence et 
al., 1979). It characterizes four basic types of OI (I-IV) on the basis of clinical, radiological and 
inheritance patterns of the condition (Table 1). The numbers of types do not represent severity of 
OI form, but were given accordingly to a description order of OI group.  
 
1.3.1.1 OI Type I (Classical non-deforming OI with blue sclera) 
OI Type I is a mild, non-deforming form of OI, caused by autosomal dominant mutations in the 
COL1A1 and COL1A2 genes. Patients develop haploinsuffiency of collagen type I (Roughley et 
al., 2003). The incidence of OI Type I is about 1 per 10,000 to 20,000 births.
1
 The disorder is 
defined by osseous fragility, mild joint hypermobility, blue eye sclera, easy bruising, progressing 
hearing loss and progressing scoliosis. Blue sclera is developing due to thin collagen layers so 
that the choroid layer shines through. Patients usually develop near normal stature with slightly 
reduced height and a tendency to shorten with age. Height reduction is caused by insignificant 
lower limb and spinal deformity as well as the consequences of spinal osteoporosis – progressive 
platyspondyly and kyphosis (Sillence et al., 1979) (Figure 4a). Some patients have specific – to 
OI – appearance with increased head circumference and triangular face. Skull radiographs can 
show islands of irregular calcification. Hearing loss usually develops during the third decade, 
although in the most severe hearing impairment cases, it is noticed within the second decade of 
life (Sillence et al., 1979). Dentinogenesis Imperfecta and considerable bone deformity cases are 
rare. The first fractures occur at birth or during juvenile period. Patients are able to walk 
independently. The number of fractures varies individually and usually decreases after puberty. 
A new wave of susceptibility to fractures starts in menopausal females and males of early sixties, 
due to the development of osteoporosis (Sillence et al., 1979; Basel et al., 2009; Roughley et al., 
2003). 
 
1.3.1.2 OI Type II (Perinatally lethal OI) 
OI Type II is the most severe, perinatal lethal form of OI. Fetuses are spontaneously aborted or 
die during the first days after birth (Sillence et al., 1979). The prevalence of OI Type II remains 
unknown. Individuals rarely succeed to survive more than few days. Death is a result of 
pulmonary insufficiency caused by small thorax, rib fractures, or flail chest. Intrauterine bone 
fractures, severe skeletal deformity, severe limb shortening, rhizomelia, diminution of calvarial 
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thickness, dark blue-black eye sclera, and small height and weight are present. The skull is soft, 
due to decreased mineralization, and large in proportion to the whole body. Femur tends to be 
crumpled (accordion-like) and angulated. The presence of beaded ribs, platyspondyly, fractures 
and deformity of shafts of bones of upper limbs is usually noticed (Sillence et al., 1979). OI 
Type II arises from parental mosaicism for autosomal dominant mutations in the COL1A1 and 
COL1A2 genes (Edwards et al., 1992). Autosomal recessive mutations in genes, connected with 
collagen type I post-translational modification, folding, transport or osteoblast proliferation and 
cell signaling, also may cause OI phenotype, overlapped with OI Type II (Basel et al., 2009; 
Roughley et al., 2003; Marini et al., 2007). 
 
1.3.1.3 OI Type III (Progressively deforming OI with normal sclera) 
OI type III is the most severe survival form of OI with heterogeneous clinical symptoms with the 
incidence of 1 per 60,000 to 100,000.
1
 The third type of OI is defined with extreme bone fragility 
and progressive severe skeletal deformity - bones are twisted and bowed. Skeletal deformities 
are caused by mechanical forces of muscles or past fractures. Severe spinal deformity in adults is 
also observed. Other symptoms include: severe scoliosis, multiple fractures at birth, extremely 
high number of fractures during whole life, Wormian bones, Dentinogenesis Imperfecta, and 
ligamentous laxity in childhood (Sillence et al., 1979). Mobility of patients is available with 
assistance. With aging, individuals develop short stature - less than 1 m for adults (Figure 4c). 
Eye sclera is usually relatively normal – white, slightly grayish or pale blue, with the tendency to 
lose dense during aging. Triangular facial shape, and temporal and occipital bossing give patients 
typical OI appearance (Sillence et al., 1979). Progressive hearing loss begins in puberty. OI Type 
III is caused by autosomal de novo dominant mutations in COL1A1, COL1A2 and autosomal 
recessive mutations in genes connected with collagen modifications and transport, osteogenic 
cells proliferation or signaling pathways in bone tissue (Basel et al., 2009; Roughley et al., 2003; 
Marini et al., 2007).  
 
1.3.1.4 OI Type IV (Common variable OI with normal sclera) 
OI type IV is the most diverse group of phenotypes, varying from mild to severe forms of 
osseous fragility. Skeletal deformity is moderate (Figure 4b). Blue sclera tends to lighten after 
birth and results in normal scleral hue. The stature is shorter than in OI type I (Sillence et al., 
1979). DI and Basilar invagination, scoliosis and osteoporosis are also present. The pattern of 
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inheritance is autosomal dominant. OI IV associated mutations are present in COL1A1 and 
COL1A2 genes (Basel et al., 2009; Roughley et al., 2003).  
 
 
 
 
 
 
 
 
 
Figure 4 Radiographs of adults with OI types I (a), III (c), IV (b) (Reeder and Orwell, 2006). 
 
1.3.2  Modern OI classification 
After the discovery of non-collagen genes connected with OI, the original Sillence classification 
was expanded. In 2010, the International Nomenclature Group for Constitutional Disorders of 
the Skeleton suggested adding of the fifth OI type (OI Type V with calcification of interosseous 
membranes) to the classical OI types to avoid confusing molecular references in the clinical 
classification (Table 1). OI Type V was distinguished separately, due to special histological 
traits, which differed from changes in bone architecture of the previously described OI types. 
(Van Dijk et al., 2010; Glorieux et al., 2000).   
 
1.3.2.1 OI Type V (OI with calcification of interosseous membranes) 
Some phenotypes of OI Type IV differ during histological analysis of the bone tissue. These 
forms were distinguished in separate OI type. OI Type V is moderately deforming OI form with 
moderate to severe bone fragility (Glorieux et al., 2000). Blue sclera, ligament laxity and DI are 
absent. Mostly, the height of patients is short but some are above average. Hearing loss and 
(a) (b) (c) 
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Wormian bones are rare. Scoliosis was found in half of the patients. Skin, tendon, ligament, and 
fasciae have normal texture. Chest wall, elbow and forearm deformities may be present (Kim et 
al., 2013). Special traits of OI Type V is hypertrophic callus in fracture sites, calcification of 
interosseous membranes, non-traumatic radial head dislocation, metaphyseal radiodende band 
adjacent to growth plates upon X-ray (Cheung  et al., 2007) (Figure 5a). Moreover, lamellar 
organization of the bone has an irregular mesh-like (butterfly-like) appearance (Figure 5b). OI 
Type V arises as a result of heterozygous mutations in the 5’ untranslated region (5’UTR) of the 
IFITM5 gene (Lazarus et al., 2014). Recently, missense mutations causing OI type V in coding 
regions of IFITM5 were also found (Farber et al., 2014; Guillén-Navarro et al., 2013). 
               
 
 
 
 
 
 
 
Figure 5 (a) Radial head dislocation and hypertrophic callus formation in a patient with OI type V  
(b) Irregular mesh-like pattern of bone tissue in a patient with OI type V (Lee et al., 2006). 
 
Table 1 OI Syndrome nomenclature according to International Nomenclature Group for 
Constitutional Disorders of the Skeleton (INCCDS) 2010* (Shapiro et al., 2013). 
Syndrome Name OI Numerical Type Subtypes 
Classical non-deforming OI with blue sclera I 2 
Common variable OI with normal sclera IV 2 
OI with calcification of interosseous membranes V 1 
Progressively deforming OI with normal sclera III 12 
Perinatally lethal OI II 6 
*Syndromes are listed in order of increasing severity 
(a)        (b)        
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1.3.3  Genetic OI classification 
Genetic classification is based on the inheritance pattern and molecular mechanisms of an OI 
type. Each gene, affected by pathogenic OI mutation, generally forms a discrete OI type. Besides 
types I-V, genetic classification differs OI types VI-VII (Glorieux et al., 2002; Homan et al., 
2011) and additional OI type VIII (Cabral et al., 2007). Also, the alternative classification 
suggests the presence of extra OI types IX-XV (Van Dijk et al., 2010; Barnes et al., 2006, 
Christiansen et al., 2010; Martinez-Glez et al., 2012; Shaheen et al., 2012; Pyott et al., 2013; 
Barnes et al., 2006) (Table 2). The difficulty stands in clinical impractice of such system, as 
many phenotypes tend to overlap. For example, types VII and VIII are sometimes excluded due 
to concordance of clinical and radiological features with types II-IV. Also, clinical OI 
classification usually considers genetic OI types VI-XV as subtypes of an OI type III. 
 
Table 2 Genetic OI classification (Shapiro et al., 2013) 
OI Type Phenotype severity Inheritance Gene OMIM  
I Mild, non-deforming AD COL1A1 #166200 
II Perinatal lethal AD/AR COL1A1, COL1A2, 
CRTAP, LEPRE1, 
PPIB, CREB3L1 
#166210 
III Severe, deforming AD/AR COL1A1, COL1A2, 
CRTAP, LEPRE1, 
PPIB 
#259420 
IV Moderately deforming AD COL1A1, COL1A2 #166220 
V Mild to moderately deforming AD IFITM5 #610967 
VI Hyperosteoidosis AR SERPINF1 #613982 
VII Moderately deforming AR CRTAP, LEPRE1 #610682 
VIII Severe, lethal AR CRTAP, LEPRE1 #610915 
IX Moderate to severe phenotype AR PPIB #259440 
X Moderate to severe phenotype AR SERPINH1 #613848 
XI Moderate to severe phenotype AR FKBP10 #610968 
XII Moderate to severe phenotype AR OSX/SP7 #613849 
XIII Moderate to severe phenotype AR BMP1 #614856 
XIV Moderate to severe phenotype AR TMEM38B #615066 
XV Moderate to severe phenotype AR WNT1 #615220 
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1.3.4  Brittle bone overlap phenotypes 
Cases of Osteogenesis Imperfecta that overlap with Ehlers-Danlos syndrome (EDS) and Bruck 
syndrome (BS) are not rare. EDS is an inherited connective tissue disorder with a variety of 
genotypes and phenotypes. EDS is characterized by hyperextensibility of skin, fragility of 
connective tissues and joint hypermobility. The classification of EDS suggests six major types. 
The arthroclasis type of EDS (types 7A, B) affects type I collagen. Mutations occur in N-
propeptide cleavage region of COL1A1 and COL1A2 genes for EDS type 7A and 7B 
respectively. The pattern of inheritance is AD. Individuals reveal moderate fragility, skin 
hyperelasticity, congenital bilateral hip dislocation, muscular hypotonia etc. (Beighton et al., 
1998; Steinmann et al., 1980). EDS and OI overlapping phenotypes arise if N-propeptide 
domains have not been removed and are integrated in the matrix, due to Gly mutations in first 90 
residues of α1 chain (Makareeva et al., 2008). Mutations in PLOD3 gene also cause EDS/OI 
phenotype (Salo et al., 2008). 
Bruck syndrome is a genetic disorder which combines contractures and bone fragility. The 
condition also has genetic and phenotypic heterogeneity. BS and OI phenotype overlaps are 
caused by mutations in the FKBP10 and PLOD2 genes. OI and BS severity varies from mild to 
moderate (Puig-Hervás et al., 2012; Kelley et al., 2011). 
Mutations in the PLS3 (plastin 3) gene cause X-linked osteoporosis. The T-plastin protein takes 
part in forming the links between F-actin bundles. Through the assembly of cytoskeleton the 
protein influences mechanosensing of osteocytes and bone tissue homeostasis. The disease is 
connected with osteoporotic fractures and bone mineral density (BMD) decrease. Bone 
phenotypes overlap with mild OI (Van Dijk et al., 2013; Fahiminiya et al., 2014). 
 
1.4  Genetic and molecular mechanisms of OI 
Genetic background of the condition includes mutations in 16 different collagen and non-
collagen genes responsible for osteogenesis processes. It explains the range of expressivity of OI 
phenotypes. About 60% (OI Type I, IV) – 100% (OI Type II, III) cases of OI arise as a result of 
de novo mutations (Shapiro et al., 2013). Parental gonadal and somatic mosaicism occurs in 3-
5% of OI cases. The frequencies of OI type occurrence vary depending on geographical location, 
and OI type and phenotype definition of a patient. The proportion of recessive cases may be 
higher in some populations due to founder effect, such as LEPRE1 mutations in West Africans 
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and African Americans (Cabral et al., 2012). Also, OI frequencies are higher in populations, 
where inbreeding and consanguineous unions are more common. To sum up, intrafamilial and 
interfamilial heterogeneity of the phenotype severity can be explained not only by affected the 
gene and a particular kind of mutation in it but also by the pattern of inheritance. It was also 
hypothesized that OI mutations tend to accumulate severity in subsequent generations (Moraes et 
al., 2012). OI phenotype variability is also explained through incomplete penetrance. In some 
families, OI genotype may segregate phenotypic manifestations of OI. Such bias may occur due 
to differences in gene transcription, expression levels or the presence of modifying genes (Miko, 
2008). Similar ectopic overexpressivity of a wild-type allele, due to variations in promoter 
regions, was reported for patients with Marfan syndrome (Li et al., 2008).  
 
1.4.1   COL1A1 and COL1A2 genes  
OI Sillence classical types (I-IV) are caused by dominant or recessive mutations in collagen type 
I genes COL1A1and COL1A2. Mutations can lead to pathogenic biosynthesis of collagen and, as 
a result, collagen I structural dysfunction.  
The COL1A1 gene encodes for collagen type I α1 chain. It consists of 51 coding exons. OI 
mutations are identified in all exons, apart from exon 4. Exon 37 is supposed to be the richest of 
OI-associated mutations (Shapiro et al., 2013). In addition to Osteogenesis Imperfecta types I-
IV, mutations in COL1A1 can lead to Ehlers-Danlos syndrome type VIIA, Ehlers-Danlos 
syndrome classical type, Caffey disease, idiopathic osteoporosis and dermatofibrosarcoma 
protuberans (Dalgliesh, 2008)
3
. 
The COL1A2 gene encodes for collagen type I α2 chain. The gene is composed of 52 exons. No 
mutations are found in exons 1, 2, 5, and 10 but a lot of variants occur in exon 19 (Shapiro et al., 
2013). Besides OI types I-IV, mutations in COL1A2 cause EDS VIIB, recessive EDS of the 
classical type, idiopathic osteoporosis, and atypical Marfan syndrome (Dalgliesh, 2008)
4
. 
Symptoms are less severe than in case of mutations in the COL1A1 gene, due to the fact that only 
one α2 chain is incorporated into triple helix compared to two α1 chains (Dalgliesh, 2008)4. 
However, lethal mutations may appear in both genes.  
_______________________ 
3 
http://www.ncbi.nlm.nih.gov/gene/1277  
4 
http://www.ncbi.nlm.nih.gov/gene/1278   
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1.4.1.1 Molecular mechanisms of OI mutations in collagen 
Collagen gene mutations are divided into two types – quantitative and qualitative defects. In the 
case of quantitative defect, haploinsufficiency takes place. Collagen structure is normal but there 
is a lack of collagen in bone matrix. Only half of the normal amount of collagen is synthesized, 
because transcription of the mutated allele is interrupted with premature termination (PTC). 
Then, nonsense-mediated mRNA decay (NMD) is activated, and defective transcripts are 
degraded (Marini and Blissett, 2013).  The rest of the matrix contains structurally normal 
collagen fibrils with proα1 and proα2 chains from a normal allele. A reduced number of collagen 
fibrils deposited in the ECM causes improper structure and integrity of ECM. 
Dominant OI types II-IV result from mutations which alter collagen I quality. Collagen triple 
helix is extremely sensitive to alterations. The structure of collagen fibrils is changed due to 
single nucleotide substitutions in COL1A1 and COL1A2 genes. If glycine residues are substituted 
in proα1 or proα2 chains, the helical folding of collagen is postponed, and post-translational 
overmodification occurs. Phenotypes vary from mild forms of osteopenia to lethal forms.  
1/5 and 1/3 of Gly substitutions in proα2 and proα1 chains, respectively, are lethal. Especially 
severe impact is caused by substitutions of Gly with branched nonpolar or charged amino acids 
(Glu, Arg, Asp, Val) (Marini et al., 2007). The degree of severity of a disorder, based on 
substituted residues, is – the following – Ala ≤ Ser < Cys < Arg < Val < Glu ≤ Asp (Beck et al., 
2000). The more bulky amino acid incorporates into a collagen triple helix, the more 
unstructured collagen fibrils are. As a result, bones tend to be more fragile (Figure 6). 
 
 
 
 
 
 
 
Figure 6 Collagen triple helix (Pro-Pro-Gly)10 cross-section. Gly residues – dark blue, X residues – dark 
grey, Y residues – light grey. A circle illustrates normal diameter of the triple helix. 
(a) Normal, (b) Gly substitution with Ser, (c) Gly substitution with Val. (Shapiro et al., 2013). 
(b) (c) (a) 
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Lethal Gly substitutions in proα1 chain are located in MLBR2 and MLBR3 (Makareeva et al., 
2008). Proα2 chain’s lethal Gly substitutions are aligned with proteoglycan binding sites. Current 
data reveals the importance of collagen monomer interactions with NCPs – fibronectin, decorin, 
integrins, and matrix metalloproteinases (MMPs) (Marini et al., 2007; Forlino et al., 2011). Gly 
substitutions in N-proteinase cleavage sites can disrupt procollagen modification and cause mild 
OI and EDS.  
Mutations in C-proteinase cleavage site do not interfere with posttranslational modification. 
Incorporated into fibrils uncleaved pC-collagen results in increased mineral density and high 
BMD OI (Lindahl et al., 2011). Single nucleotide substitutions of X and Y positions in Gly-X-Y 
triplets cause significant frameshifts and prevent normal processing of propeptide, leading to 
combined OI/EDS condition. Substitutions of glycine at the same position may cause distinct 
forms of OI. Recently, p.Gly1088Glu and p.Gly1088Ala mutations were reported to cause OI 
type I and lethal OI respectively (Xia et al., 2014). 
Whole gene deletions of COL1A1 result in haploinsufficiency and OI Type I phenotype. Multi-
exon deletions of exons 23 to 25 (Barsh et al., 1985; Chu et al., 1985), 39 to 48 (Bodian et al., 
2009) cause OI Type II. Whole gene deletions of COL1A2 are not identified. Deletions of exons 
7 to 11, 39 to 40 cause OI Types I and II respectively (Mundlos et al., 1996; Willing et al., 
1988). Collagen splice site mutations result in exon skipping, intronic retention, intron or exon 
cryptic splice site activation. Described frameshifts lead to PTC. Phenotypes develop mostly 
mild OI (Marini et al., 2007).  
 
1.4.2  Non-collagenous OI genes 
Mutations in non-collagenous genes, apart from the IFITM5 gene, respond to OI types with 
autosomal-recessive (AR) pattern of inheritance. OI is caused by defects of the mineralization 
(type V, VI OI; IFITM5, SERPINF1 genes), collagen-3 hydroxylation defects (types VII-IX OI; 
CRTAP, LEPRE1, PPIB genes), collagen chaperones (types X, XI; SERPINH1, FKBP10 genes), 
and C-propeptide cleavage enzyme (type XII, the BMP1 gene). Defects of three more 
unclassified types of OI are connected with the WNT1, TMEM38B, OSX, and CREB3L1 genes 
(Supplementary Figure 2).   
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1.4.2.1 The IFITM5 gene 
Interferon induced transmembrane protein 5 (IFITM5) gene encodes for a 14,8 kDa 
transmembrane protein bone-restricted Ifitm-like protein (BRIL) which is expressed specifically 
in skeleton. BRIL is important for collagen mineralization and is highly expressed in osteoblasts 
(Lazarus et al., 2014). Mineralization contribution can be direct through interactions with ECM 
or indirect via association with the membrane or intracellular mediators. BRIL connects directly 
to a FKBP10 gene product - FK506 binding protein 10, which is known to take part in collagen 
folding via peptidyl-prolyl cis-trans isomerase activity. It is also possibly involved in the late 
stage of osteoblast maturation (Hanagata and Li X, 2011).  
Previously all patients with OI type V were supposed to have the same heterozygous mutation in 
5’UTR of the IFITM5 gene. The mutation causes in-frame alternative initiation codon upstream 
of the annotated translation initiation codon. As a consequence, five amino acid residues (Met-
Ala-Leu-Glu-Pro) are added to N-terminus of a protein (Semler et al., 2012; Cho et al., 2012). 
Recently, heterozygous missense mutation in a coding region of the IFITM5 gene was also found 
(Hoyer-Kuhn et al., 2014). Patients with the same mutations in the IFITM5 gene develop distant 
phenotypes, even within one family. Generally, phenotypes are comparable to autosomal 
dominant non-collagen OI type V (Farber et al., 2014). 
 
1.4.2.2 The SERPINF1 gene 
The gene encodes for a serpin peptidase inhibitor, clade F (pigment epithelium-derived factor or 
PEDF). PEDF is a 50 kDa secreted glycoprotein, inhibitor of angiogenesis. Protein is highly 
expressed in osteoblasts, and is an important factor for bone homeostasis, matrix remodeling in 
particular (Becker et al., 2011). Possible ways of PEDF control of bone homeostasis include – 
binding to ECM via collagen and glucoseaminoglycans binding motifs; regulation of 
intracellular signaling pathways, such as Notch and WNT; and modulation of nuclear signaling 
(Yasui et al, 2003; Hosomichi et al., 2005). PEDF controls mineral deposition into ECM (Bogan 
et al., 2013), and is supposed to inhibit osteoclast activity and bone resorption (Akiyama et al., 
2010).  
Nonsense and frameshift mutations in this gene result in PTC and NMD of its transcripts (Becker 
et al., 2011; Rauch et al., 2012). Defects in the SERPINF1 gene provide severe deforming OI 
type VI (Cho et al., 2013; Rauch et al., 2012). The exact molecular mechanism of the current OI 
type remains unknown. A patient with both recessive null-mutation in SERPINF1 and non-
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classical IFITM5 mutation was reported. BRIL and PEDF expression differed from the 
expression levels in patients with IFITM5 and SERPINF1 mutations. As a result, mutual 
influence of PEDF and BRIL was predicted (Hoyer-Kuhn et al., 2014). 
 
1.4.2.3 CRTAP, LEPRE1 and PPIB genes 
Proline residues of collagen type I α1 and α2 chains (Pro986 of α1 and α2 chains and Pro707 of 
α2 chain) are modified by a heterotrimeric prolyl 3-hydroxylation complex, situated on 
endoplasmatic reticulum (ER).  
The prolyl-lysyl-hydroxylase modification of procollagen provides intermolecular cross-links 
and stability of protein by attaching binding sites to carbohydrate units. This activity is crucial 
for collagen folding, protein-collagen interactions assembly, transport to extracellular matrix 
and, as a result, bone formation. Cofactors for the enzyme are iron and ascorbate. In addition to 
hydroxylase activity, the complex acts as a peptidyl-prolyl cis-trans isomerase (PPIase) and 
collagen chaperone (Forlino et al., 2011). The activity of the complex is specific to Pro position 
and collagen substrate. The complex is composed of cartilage-associated protein, prolyl-3-
hydroxylase and cyclophilin B proteins, coded by CRTAP, LEPRE1, and PPIB genes 
respectively. Mutations in this complex cause some of the most severe phenotypes of OI.
 
The CRTAP gene encodes for a cartilage-associated protein (CRTAP) – a helper protein of the 
complex. It is highly expressed in chondrocytes of growth plates (Morello et al., 2006). The 
scaffolding protein controls the activity of proteins of the cytohesin/ARNO family in response to 
cell stimuli. CRTAP protein shows dependent costabilization with the product of the LEPRE1 
gene (leucine proline-enriched proteoglycan 1). Mutations in either of these genes lead to the 
absence or reduced amounts of CRTAP and prolyl 3-hydroxylase 1 (P3H1) (Chang et al., 2010). 
The majority of mutations were identified in the first or fourth exon and surrounding introns. The 
defects of CRTAP cause NMD of the transcripts and deficiency of a CRTAP protein, where 3-
hydroxylation complex activity is lost. Pro986 of procollagen α1 chain stays unhydroxylated. 
The collagen helix is overmodified by lysyl hydroxylase and prolyl-4-hydroxylase instead. The 
folding of collagen is delayed, as in the case of defects in C-termini of procollagen (Barnes et al., 
2006). Thus, phenotypes of CRTAP deficient OI type VII overlap with Sillence classical OI 
types II and III.  
LEPRE1 gene product is a leprecan (P3H1). Leprecan provides prolyl 3-hydroxylase enzymatic 
function. The P3H1 protein has the same N-terminal domain as a CRTAP protein does. It is also 
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known as a tumor suppressor factor and signal molecule, providing intracellular communication 
(Cabral et al., 2007, Van Dijk et al., 2011). Homozygous and compound heterozygous mutations 
of the LEPRE1 gene usually occur in exons 13, 15 and 5, and result in leprecan deficient cells. 
Splice-site mutations in the fifth exon bring alternative spliced transcripts with PTC (Cabral et 
al., 2007). LEPRE-null fibroblasts produce up to 50% more collagen. Collagen is over-modified 
and lacks 3-prolyl-hydroxylation of Pro986 in proα chain, as in the cases of CRTAP deficiency. 
Null-alleles of LEPRE1 result in connective tissue disorders, equivalent to Osteogenesis 
Imperfecta type VIII, phenotypically similar to OI type VII (II, III). 
The PPIB (also known as a CYPB) gene codes for peptidyl-prolyl cis-trans isomerase B 
(cyclophilin B, CyPB). CyPB is the third component of the hydroxylation complex and contains 
cyclophilin-like PPIase domain. Cis-trans isomerase activity of CyPB changes the configuration 
of cis to trans-conformers, since only prolyl-containing trans-peptide bonds can be included into 
collagen triple helix (Van Dijk et al., 2009; Pyott et al., 2011). CyPB affects the folding of the 
Pro-rich regions of procollagen’s C-termini, procollagen export and secretion with HSP47 
protein. Deficient CyPB amount leads to inappropriate collagen helical folding, post-
translational over modification and 3-hydroxyprolyl deficiency, forming OI type IX. Phenotype 
overlaps with phenotypes of OI types VII and VIII (II, III). 
 
1.4.2.4 FKBP10 and SERPINH1 genes 
Procollagen type I folding into triple helix is assisted by chaperones a 65 kDa FK506 binding 
protein 10 (FKBP65) and heat shock protein 47 (HSP47). These chaperons form ER resident 
complex.  
HSP47 is coded by the SERPINH1 gene (serpin peptidase inhibitor, clade H, member 1); it is a 
procollagen molecular chaperon. The protein prevents immature collagen folding. Due to defects 
of the SERPINH1 gene, the distribution of procollagen to endoplasmic reticulum does not occur. 
Improper helical folding of collagen results in OI type X (severe progressive OI).  
The FKBP10 gene encodes for FKBP65. Protein can be secreted or binded to ER membrane. 
FKBP65 takes part in protein quality control and folding (Kelley et al., 2011). FKBP65 takes 
part in lysyl hydroxylation by stabilizing the lysyl hydroxylase 2 (LH2) enzyme or promoting 
interaction between LH2 and substrate through PPIase activity (Barnes et al., 2012; Schwarze et 
al., 2013). Mutations in FKBP10 gene result in the reduced amount of hydroxylated lysyl 
residues of procollagen in bone matrix as well as reduced collagen amount in ECM due to 
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reduced collagen cross-linking (Barnes et al., 2012). Apart from OI type XI, phenotype defects 
of this gene can show contractures without OI (Yup’ik syndrome) and contractures combined 
with OI (Bruck syndrome). 
 
1.4.2.5 The BMP1 gene 
The product of the BMP1 gene – bone morphogenetic protein 1 (BMP1) – participates in bone 
and cartilage formation. BMP1 has peptidase activity and cleaves C-terminal propeptides of 
procollagen I, II and III. The enzyme also proteolytically activates lysyl oxydase. BMP1 
increases the expression of collagen type 1 and osteocalcin in osteoblasts, promoting tissue 
mineralization and acting as a regulator of bone repair. BMP1-3 isoforms circulate in blood and 
can be used as bone biomarkers (Martinez-Glez et al., 2012; Asharani et al., 2012, Grgurevic et 
al., 2011).  
Mutations in the BMP1 gene can alter catalytic peptidase domain or BMP1 signal peptide. 
Phenotypes are close to severe AR OI and are distinguished as an OI type XII with increased 
mineral density and recurrent fractures, as in the case of C-termini cleavage defects of 
procollagen (Asharani et al., 2012). However, BMP1 protein has a range of substrates, and 
phenotype development of the condition may be connected with other molecular mechanisms. 
 
1.4.2.6 The OSX gene 
The OSX/SP7 gene encodes osterix (OSX) – a zinc-finger transcription factor. Protein is bone-
specific and connected to osteoblast differentiation and bone development. It contains N-
terminal trans-activation motifs and three Cys2-His2 C-termini zinc finger DNA-binding 
domains. The described AR OI mutations cause deletion of one of the zinc finger domains. 
Detailed pathogenesis of an osterix-defficient OI type XIII remains unknown. OSX/SP7 OI 
mutations are very rare, which are mainly deleterious mutations incompatible with life 
(Lapunzina et al., 2010). 
 
1.4.2.7 The TMEM38B gene 
The TMEM38B gene (a transmembrane protein 38B) encodes a TRIC-B, ubiquitous component 
of the monovalent cation-specific transmembrane channel (TRIC), responsible for the release of 
calcium cations from intracellular stores, such as ER and sarcoplasmatic reticulum. Mutations in 
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this gene can lead to autosomal recessive OI type XIV (non-syndromic form of OI) (Volodarsky 
et al., 2013; Shaheen et al., 2012). 
 
1.4.2.8 The WNT1 gene 
The WNT1 (Wingless-type MMTV integration site family, member 1 (INT1, BMND16)) gene 
encodes for secreted signaling protein. The WNT1 gene participates in body axis patterning, cell 
differentiation, migration, and proliferation. WNT1 activates canonical low density lipoprotein 
receptor-related protein 5 (LRP5) – mediated WNT/β-catenin signaling pathway which regulates 
gene expression in osteoblasts. As a result, the gene is supposed to influence bone development 
(Keupp et al., 2013; Laine et al., 2013). 
Heterozygous and variant homozygous mutations in WNT1 gene can induce bone fragility – age-
related osteoporosis and severe recessive forms of OI indicated as OI type XV respectively 
(Pyott et al., 2013; Fahiminiya et al., 2013; Keupp et al., 2013; Laine et al., 2013). Patients with 
mutations in WNT1 do not respond to bisphosphonate therapy. Bisphosphonates inhibit 
osteoclast activity and bone resorption, whereas WNT1 mutations cause dysfunction of 
osteoblasts (Keupp et al., 2013). 
 
1.4.2.9 The CREB3L1 gene 
The CREB3L1 (cAMP responsive element binding protein 3-like 1) gene encodes for ER-stress 
transducer protein OASIS (Old Astrocyte Specifically Induced Substance). During ER-stress 
protein activates the unfolded protein response target genes (Omori et al., 2002). Mutations in 
this gene cause severe osteopenia, spontaneous fractures, as in severe recessive OI. Protein 
regulates tissue-specific gene transcription. Protein is also supposed to influence procollagen 
synthesis by osteoblasts (Symoens et al., 2013). 
 
1.4.3  Genetic diagnosis of OI  
Clinical diagnosis of OI should be confirmed by genetic diagnosis, since phenotypes of different 
disorders tend to overlap. Firstly, the COL1A1 and COL1A2 genes are screened for mutations. 
As mentioned above, about 90% of OI cases are caused by mutations in collagen genes. If no 
causative mutations are detected, the sequencing of non-collagen genes, included into the 
recessive OI panel, occurs. All new causative variants are checked with functional analysis. For 
29 
 
this purpose, collagen expression analysis with mRNA/complementary DNA (cDNA) and 
proteins from cultured skin fibroblasts is done. It may reveal abnormalities in procollagen 
structure or expression. If no mutations in the known genes are found, the patient may have a 
mutation in an undiscovered OI gene (Van Dijk et al., 2012) (Figure 7). 
 
 
 
 
 
 
 
Figure 7 The workflow of genetic diagnostics for an OI patient (Van Dijk et al., 2012). 
 
 
1.5 Exome sequencing as a tool for Mendelian disorder gene discovery 
Genetic causes of more than 3,000 single-gene disorders with known phenotypes (1/5 of OMIM 
database queries) remain unidentified. However, after next-generation sequencing (NGS) 
approaches became available, more than 100 genes causing Mendelian disorders were revealed 
(Rabbani et al., 2012). The majority of discovered mutations alter the coding regions of genes, 
which makes sequencing of the exon regions a constructive approach for the discovery of new 
genes and mutations connected with Mendelian disorders (Bamshad et al., 2011; Ku et al., 
2011). Such selective sequencing of protein-coding regions of the genome is provided by exome 
sequencing studies. It is a rapid, high-throughput, sensitive and a cost-effective strategy of gene 
discovery for Mendelian disorders, compared to Whole Genome Sequencing (WGS).  
The estimated number of exons in the human genome is about 180,000, with the length equal to 
27.9 Mb, composing about 1% of the whole human genome (Ng et al., 2009). In addition to 
exons, exome sequencing kits also include flanking intron regions, UTR regions, promoters, 
miRNA genes and non-coding RNAs, which may affect gene regulation and functioning 
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(Bamshad et al., 2011). Annotated and unknown regions remain uncovered because exome 
sequencing methods are mostly based on sequence information from consensus coding sequence 
(CCDS) and RefSeq databases (Ku et al., 2011). The analysis of copy number variations (CNV) 
and other structural variations is limited as well (Gilissen et al., 2011). Some regulatory regions 
and evolutionary conserved motifs miss covering as well. It does not affect the method’s 
sensitivity as non-synonymous variants have weak or absent effect in non-coding regions. At the 
same time, pathogenic missense or nonsense substitutions and indels in exons are more 
important as they cause fitness decrease and are deleterious. SureSelect Human All Exon kit V5 
(Agilent Technologies Inc.) includes 70 Mb of human genome. The reduction of sequence 
volumes allows to deepen sequencing coverage up to 60-65x and increase the method’s 
sensitivity (Ng et al., 2010).  
Previously, OI was supposed to arise due to mutations in collagen type I (COL1A1 and COL1A2) 
genes. 14 other OI genes were recently revealed with Sanger sequencing, real-time quantitative 
polymerase chain reaction (RT-qPCR), linkage analysis, homozygosity analysis, and NGS. In 
some OI patients, mutations in known OI genes are absent, which remains a great interest to 
investigators. Traditional methods, such as linkage analysis, lose effectiveness if they have to 
deal with the limited number of affected individuals, de novo mutations, unrelated patients and 
phenotypic heterogeneity (Ku et al., 2011), which are common features for OI disorders 
(Roughly et al., 2003). In this case, exome sequencing represents the most effective method for 
the discovery of new OI genes and mutations. A few novel OI genes have been discovered with 
the assistance of exome sequencing. Among these OI genes are SERPINF1 (Becker et al., 2011), 
WNT1 (Pyott et al., 2013), IFITM5 (Cho et al., 2012), and PLOD2 with BS/OI overlap 
phenotype (Puig-Hervás et al., 2012).  
 
1.5.1  Strategy of exome sequencing and detecting disease-causing variants  
The algorithm of exome sequencing is as follows:  
Firstly, the DNA is randomly cleaved, and a shotgun in vitro library is formed. Then, DNA 
segments are flanked with adaptors. Probes are hybridized with biotinylated DNAs or RNAs. 
Biotin-streptavidin connections allow the capturing of probes to array for exome enrichment. 
Then, amplification and massively parallel sequencing take place. Finally, potential causal 
variants are detected and mapped (Bamshad et al., 2011). Bar-coding, which is done during 
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library construction or amplification, allows sequencing of a multiple number of samples at the 
same time (up to 16) (Ku et al., 2011).  
Data is processed in order to find rare variants, shared between unrelated or closely related 
patients. There are four basic strategies of gene discovery. The first one is based on the 
sequencing and filtering of unrelated affected individuals. Exome analysis identifies the variants 
common for all affected patients. Polymorphisms that are found in healthy controls or public 
variant databases (dbSNP, 1000 Genomes Project) are excluded (Figure 8a). Another way is to 
sequence and filter affected individuals from a single family. If mapping data is not available, 
sequencing of the two most distantly related affected individuals will be best. If mapping data is 
accessible, sequenced individuals have to share the smallest single haplotype (Figure 8b). 
Parents-child trio analysis is successful for detecting de novo mutations. Affected offspring will 
have unique variant, which was not inherited from parents but arose as a result of spontaneous 
mutation (Figure 8c).  
Extreme phenotype approach is based on the principle of fitness. Therefore, affected individuals 
will concentrate in one extreme of phenotype distribution (Figure 8d). In case of rare recessive 
disorders, filtering mostly uses minor allele frequency (MAF) below 1%. Moreover, to promote 
variant selection, alleles can be classified by functional consequence and biological function 
(Bamshad et al., 2011; Ku et al., 2011).  
 
 
 
 
 
 
 
 
Figure 8 Basic gene discovery strategies in exome sequencing analysis. (a) Sequencing of unrelated 
affected individuals; (b) Sequencing of multiple affected individuals from a single pedigree; (c) 
Sequencing of a parent-child trio; (d) Comparing phenotype distribution extremes (pointed at with an 
arrow red crosses represent affected phenotypes) (Bamshad et al., 2011). 
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1.6  OI in Estonia 
Since 1995 the center for clinical follow-up, treatment and research of OI in Estonia is the Clinic 
of Traumatology and Orthopaedics of Tartu University Hospital. During this period, patients 
from 32 families from different counties of Estonia are treated and investigated in Tartu 
University Hospital. Taking into account that prevalence of OI is 1 per 20,000 to 30,000 it is 
close to 100% of patients in Estonia.  
The aim is to help people with Osteogenesis Imperfecta with medical and surgical treatment, to 
improve quality of life of OI patients, and provide support for the families. At the same time, 
with clinical follow-up the genealogical information, clinical and medical history and phenotype 
description of OI patients and family members are collected to OI database for a future research. 
Additionally, blood samples for bone markers, DNA and RNA analysis are collected from all 
available family members. (Maasalu et al., 2003). 
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2. EXPERIMENTAL PART 
 
2.1  Aim of the study 
The main aim of this study is to perform exome sequencing analysis in three selected Estonian 
families with OI history in order to identify causative mutations of the disorder. 
The study includes: 
1. Description of genealogical information of the selected families with OI history.  
2. Overview of phenotype manifestations of the affected OI family members. 
3. Identification of OI causing mutations with exome sequencing.  
 
 
2.2  Methods and materials 
2.2.1  Material collection and selection of families 
The OI patient database of the Department of Traumatology and Orthopaedics, Tartu University 
Hospital (Estonia) was used for selection of families for current study
5
 The study was approved 
by the Ethics Review Committee on Human Research of the University of Tartu. The 
participants included in the study or their legal representatives gave prior consent to take part in 
the study.  
OI families with unusual clinical features in phenotypes, inheritance patterns or clinical history 
were selected for priority exome analysis. On the basis of the selection criteria three families 
were selected (2, 7 and 10) with cases of severe OI (Figures 9-11). Families 2 and 10 were 
outstanding with extreme intrafamilial variety in phenotype severity. Family 7 represented the 
case of de novo mutation with phenotype of OI type II “survivor”. Every family was provided 
with genealogical information, clinical and medical history and phenotype description of the 
family members. Blood samples were collected from all available family members. 
_________________________ 
5 
http://www.kliinikum.ee/ortopeedia/  
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2.2.1.1  Registration of genealogical information and OI phenotype 
description 
The genealogical information requested included OI history in the family and family 
consanguinity data. All healthy and affected individuals of the family, miscarriages and early 
death cases were reported. Pedigree trees were created with a Progeny Free Online Pedigree Tool
 
(by Progeny Biosoftware, LLC; USA).
6
 Phenotypes and clinical history of the families were 
described previously by Dr. Katre Maasalu. 
Phenotype description was based on the following information: 
 Presence of intrauterine fractures 
 Deviations of height and weight, skeletal deformities, presence of fractures, eye sclera 
color after birth  
 Current height, weight and skeletal deformities (including scoliosis) 
 Age of the first fracture and number of fractures for current time, description of fractures 
 Walking and standing ability 
 Head and face shape 
 Eye sclera color  
 Presence of hearing loss and age when it started 
 Presence of Dentinogenesis Imperfecta 
 Additional specific features of the patient (presence of other hereditary disorders and 
health problems etc) 
 Medical history of both parents 
 
2.2.1.2  Sample collection and DNA extraction   
Blood samples were collected by employees of Tartu University Hospital. Genomic DNA 
(gDNA) was extracted from peripheral white blood cells with standard high-salt extraction 
methods and stored at −80°C until analyzing.  
 
2.2.1    Exome sequencing 
Whole-exome sequencing was performed from gDNA by the Sequencing Core Laboratory of the 
Estonian Genome Center, University of Tartu (Estonia). Exome capture was performed using the 
TruSeq Exome Enrichment kit (Illumina) following the manufacturer’s protocol. 
_________________________ 
6 
http://www.progenygenetics.com/online-pedigree/  
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DNA fragments were sequenced with Illumina HiSeq2000 with 100-bp paired-end reads. 
Sequence reads were aligned to the human reference genome (hg19, GRCh37) with the Burrows-
Wheeler Aligner (BWA, version 0.6.1) (Li et al., 2009). Exome analysis was performed in 
probands 219, 221, 234, 228 of family 2; individuals 710, 713, 716 of family 7; and probands 
1009, 1013, 1019 of family 10 (Figures 9-11). 
 
2.2.1.1  Bioinformatic analysis and variant prioritization 
 All bioinformatics analysis procedures, including variant prioritization, were conducted by 
researchers at the Estonian Genome Center (University of Tartu) as previously described 
(Nikopensius et al., 2013). Single-nucleotide polymorphisms (SNPs) and small insertion-
deletion (indels) variants were called with SAMtools (version 0.1.18), Picard tools (version 
1.60), and a Genome Analysis Toolkit (GATK, version 1.5.21) (McKenna et al., 2010; Li et al., 
2009). The main points of interest were non-synonymous mutations, insertions-deletions and 
variants in canonical splicesites, absent from public databases (dbSNP135 and the 1000 
Genomes Project). PolyPhen-2, SIFT, Alamut and Condel software tools were used to predict the 
functional effects of mutations (Kumar et al., 2009; Adzhubei et al., 2010; Gonzalez-Perez et al., 
2011).   
 
2.2.1.2  Mutation analysis with Sanger sequencing 
The validation of a novel pathogenic variant, discovered in family 7 with exome sequencing, was 
performed with Sanger sequencing. Primers for Sanger sequencing were designed with online 
tool.
7 
Primer sequence quality was checked with UCSC browser (UCSC Genome Bioinformatics 
Group).
8 
Designed primer sequences (Tm 60°C, length 22 nt, GC % 40-60%) for COL1A1 variant 
were as follows:
 
 forward primer:   5’GAAACCCAGACACAAGCAGAAC3’ 
 reverse primer:    5’TAGTAGATGACCCCAGGAGAGC3’ 
 
 
 
_________________________ 
7 
http://bioinfo.ut.ee/primer3-0.4.0/primer3/ 
8 
http://genome.ucsc.edu/  
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PCR reaction was performed with a PTC-200 Peltier Thermal Cycler (MJ Research, USA) PCR 
machine. The PCR touchdown program, used for the reaction of amplification, was as follows: 
1=95,0°; 15:00 min 
2=95,0°; 0:25 min 
3=64,0°; 0:30 min 
4=72,0°; 0:40 min 
5=Go to 2, 4 times 
6=95,0°; 0:25 min 
7=62,0°; 0:30 min 
8=72,0°; 0:40 min 
9=Go to 6, 30 times 
10=72,0°; 5:00 min 
11=6,0° forever 
PCR reaction mix was performed in a 19 μl volume which contained 10× reaction buffer B (Solis 
BioDyne, Estonia), 0,2 mM of dNTPs (Fermentas, Lethuania), 25 mM MgCl2 (Solis BioDyne, 
Estonia), 10 pmol of forward and 10 pmol of reverse praimers, 1 U Taq HOT FIREPol
®
 DNA 
polymerase (Solis BioDyne, Estonia), 50 ng of gDNA and Milli-Q water to the final volume of a 
PCR mix. Products were separated on 1,5% agarose gel electrophoresis with 0,5× TBE buffer.  
PCR products were purified, precipitated and sequenced in the Sequencing Core Laboratory of 
the Estonian Biocentre (Tartu, Estonia). Sanger sequencing was performed with Applied 
Biosystems 3730xl DNA Analyzer.
9 
Sequence reads were analyzed visually with BioEdit 
program, version 7.0.9.0.
10
  
 
 
 
 
 
_________________________ 
9 
http://www.lifetechnologies.com/ee/en/home.html   
10 
http://www.mbio.ncsu.edu/bioedit/bioedit.html 
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2.3 Results  
2.3.1 Genealogical information and phenotype description of the selected OI families 
All families included in the study are non-consanguineous families of Estonian origin. Families 2 
and 10 have history of OI segregating with AD inheritance pattern, whereas family 7 was 
analyzed as a case-parents trio to search for de novo mutation (Figures 9-11). 
 
2.3.1.1 Family 2  
Family was choosed for study due to an intrafamilial variety in phenotype severity. Probands 
219, 221, 234, and 228 were selected for exome sequencing using the strategy of multiple 
affected individuals in a single pedigree (Figure 9). The majority of family members developed 
mild bone fragility, which started in the childhood. Secondary features of OI phenotype included 
hearing loss and blue eye sclera, normal dentition. Height is normal. The number of fractures 
varied from <10 (individual 228) up to 20 (individuals 221, 234). The clinical signs are typical to 
OI type I. Proband 219 revealed distant phenotype from the rest of the affected individuals. The 
OI phenotype differs in its severity. The number of fractures is considerably higher, major 
skeletal deformations, reduced height, severe osteoporosis and triangular face are present. These 
findings are typical to type III of OI.  
 
 
 
 
 
 
 
 
 
Figure 9 The pedigree tree of family 2 with AD inheritance pattern of OI.  
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2.3.1.2 Family 10 
The case represents the diversity of OI forms within a single family (Figure 10). All affected 
family members are females, they have blue sclera, but DI and hearing loss are not present. The 
individual 1009 developed severe OI with plenty of fractures, long bones deformations, scoliosis, 
body disproportions, and significantly reduced height. The individual was clinically diagnosed 
with OI type III. The proband 1013 has mild OI with normal height. The number of fractures is 
up to 10. Individuals 1017 and 1019 have moderate OI with reduced height, and reoccurred 
fractures. The phenotype is typical to OI type IV. Exome sequencing was performed in probands 
1009, 1013 and 1019 using the strategy of multiple affected individuals in a single pedigree. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10 AD inheritance pattern of OI in family 10. 
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2.3.1.3 Family 7 
The case represents arising of a new mutation in the otherwise healthy family. Proband 716 was 
born to healthy parents (Figure 11). Ultrasound discovered delayed intrauterine development of 
the skeleton. The child was born with multiple fractures, deformations of upper and lower limbs, 
soft strained skull, and severe respiratory failure. The presence of extreme osteopenia, and 
accordion-like ribs was confirmed. The proband was clinically diagnosed with OI type II. Due to 
extreme care, the proband survived, and at the age of 14, the height of the proband was 80 cm, 
and the weight 15 kilos. Mental development was normal. The patient died from respiratory 
insufficiency at the age of 14.5 years. Exome sequencing was performed in individuals 710, 713, 
and 716 using the strategy of a parents-child trio.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11 The pedigree tree of OI family 7.  
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2.3.3 Genetic studies  
2.3.3.1 Exome sequencing in family 2 
During exome sequencing, heterozygous mutation c.1821+1G>A in intron-exon junction 26 of 
the COL1A1 gene (rs66555264 in dbSNP) was discovered in probands 219, 221, 234, 228 
(Figure 12). The mutation causes the loss of canonical splicing donor site. The c.1821 position is 
highly conserved (phyloP score 5,165) (Table 4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12 Integrative Genomics Viewer (IGV) image of chromosome 17 region: c.1821+1G>A transition 
in the COL1A1 gene in sequenced probands of family 2 (a) 219, (b) 221, (c) 234, (d) 228. Figure 
represents the sequence of the sense DNA strand. Red squares show C>T transition (complementary to 
G>A on the antisense strand). Approximately half of the reads contain mutated allele (red), indicating the 
heterozygous state of mutation. 
 
 
(d) 
(c) 
(b) 
(a) 
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2.3.3.2 Exome sequencing in family 10 
Heterozygous frameshift mutation c.1128delT (referred to as p.Gly377AlafsX164 in OI 
database) was found in exon 17 of the COL1A1 gene of probands 1009, 1013, 1019 from family 
10 (rs72645370 in dbSNP) (Figure 13). The frameshift caused by the deletion of T in position 
1128 results in the synonymous substitution of Pro376 residue. However, the appeared 
frameshift alters the following sequence, starting from Gly377, substituted with Ala residue. The 
shift frame length composes 164 bp, including stop codon (Table 4). Gly377 residue and the 
following seven amino acids are highly conserved from human up to zebrafish (Table 3).  
 
Table 3 The conservation of Gly377 residue              
in different species 
 
 
 
 
 
 
 
 
                   
   
Figure 13 The IGV image of chromosome 17: 
c.1128delT (p.Gly377AlafsX164) frameshift 
mutation in the COL1A1 gene in sequenced 
probands from family 10 (a) 1009, (b) 1013, (c) 
1019. The sequence of the sense DNA strand is 
presented above. Black stripes represent deletion 
of an A nucleotide at position 1128 
(complementary to T nucleotide for the antisense 
strand). The mutation is in heterozygous state.
 
                 Gly377 
                    ↓ 
Human G P A G A A G P 
Chimp G P A G A A G P 
Macaque G P A G A A G P 
Rat G P A G A A G P 
Mouse G P A G A A G P 
Dog G P A G A A G P 
Cat G P A G A A G P 
Opossum G P A G A A G P 
Frog G Q A G A A G P 
Zebrafish G P A G A A G P 
(c) 
(b) 
(a) 
  
2.3.3.3 Exome sequencing in family 7 
Heterozygous missense c.2317G>T (p.Gly773Cys) mutation was found in exon 33/34 of the 
COL1A1 gene in the affected proband 716 from family 7. The mutation was absent in healthy 
parents and a healthy brother of the affected proband. The presence of mutation was confirmed 
with Sanger sequencing (Figure 14). Codon 773 is highly conserved between species (phyloP 
score 5,418) (Table 4).  The deleterious effect of the mutation was confirmed in silico (Condel 
score 0,945, SIFT score 0, PolyPhen-2 score 1).  
                                                
  
 
 
 
 
 
 
 
 
 
 
Figure 14 Validation of the presence of a c.2317G>T mutation in the COL1A1 gene by Sanger 
sequencing.  
Reference  allele c.2317G in healthy family members 710 (a), 713 (b), 715 (d).  
Heterozygous c.2317G >T transversion in proband 716 (c) leads to p.Gly773Cys substitution.  
C    T    C    C     T   T   G    C    C    C    T  
P              P                 C                 P 
(a) (b) 
(c) (d) 
C    T    C    C     T   G    G    C    C    C    T  
P              P                 G                 P 
C    T    C    C     T   G    G    C    C    C    T  
P              P                 G                 P 
C    T    C    C     T   G    G    C    C    C    T  
P              P                 G                 P 
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Table 4. Mutations, discovered with exome sequencing in three Estonian OI families  
 Family 2 Family 10 Family 7 
Gene COL1A1 COL1A1 COL1A1 
Mutation c.1821+1G>A c.1128delT c.2317G>T 
Allelic state heterozygous heterozygous heterozygous 
Function splice site loss frameshift missense 
Amino acid substitution - p.Gly377AlafsX164 p.Gly773Cys 
dbSNP rs # rs66555264 rs72645370 - 
phyloP score 5,165 5,753 5,418 
Pattern of inheritance AD AD  de novo 
 
 
2.3.3.4  Epidemiological studies 
All the mutations detected were absent from the Exome Variant Server of the NHLBI-ESP 
database and the 1000 Genomes Project database. Also, 89 Estonian control exomes and 87 
Estonian full genomes were free from the presence of the pathogenic variants discovered.  
 
 
2.4  Discussion 
 
2.4.1  COL1A1 splice site mutation c.1821+1G>A causes mild OI 
Pathogenic c.1821+1G>A variant was discovered with exome sequencing in the COL1A1 gene. 
The mutation alters consensus sequence GT at the 5’ canonic splicing donor site of intron 26.  
The variant has been previously described 12 times in OI database (OI types I, IV) (Marini et al., 
2007; Qin et al., 2005; Johnson et al., 2000; etc).
2
 Two of the reported cases had OI type IV. The 
rest of the individuals revealed mild OI phenotype matched with OI type I. Our study reported 
c.1821+1G>A mutation in patients from a single family with OI type I and IV. 
The mutation causes retention of intron 26, the frame-shift and origin of the down-stream stop 
codons. Due to splice site mutations, intron retention and exon skipping depend on the length of 
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an intron. If an intron is short and has a mutated splicing site with stop codons downstream not 
further than 300 bp, as in the case of intron 26, U1RNA will consider the intronic region as a 
possible exon sequence and include it into the transcript. With mutations in splicing site of 
longer introns, exon skipping will occur (Robberson et al., 1990; Stamm et al., 2000). 
Previous studies showed the absence of transcripts of mutated allele in the cytoplasm of skin 
fibroblasts of patients with OI type I caused by c.1821+1G>A mutation (Stover et al., 1993; 
Johnson et al., 2000). The amount of mutated collagen I α1 mRNA in the nucleus was normal 
with longer half-life of altered mRNAs. Longer half-life could also be connected to the change in 
stability of mutated transcripts through the presence of additional Cis-elements in a retained 
intron (Galante et al., 2004).  
The absence of mutated mRNA in the cytoplasm was not caused by NMD but was a 
consequence of defective mRNA export (Johnson et al., 2000). Pre-mRNA undergoes a 
checkpoint of packaging and screening in SC-35 domain of the nucleus before transporting to the 
cytoplasm. The retention of introns into mRNA after splicing might prevent mRNA from leaving 
the SC-35 domain (Shopland et al., 2002; Hall et al., 2006). As a result, only half of collagen I 
α1 is translated into protein, which causes collagen quantitative deficiency and mild OI. 
The absence of mutated collagen type I α1 transcripts in the cell cytoplasm is the key difference 
between mild and severe OI. As described above, the variety in phenotype forms between 
carriers of the same mutation might come from variants in the COL1A1 promoters, which could 
change the regulation of wild-type allele expression and influence the amount of mRNA and 
translated protein in the cell. Mechanisms of mRNA export from the nucleus and NMD could 
also input into phenotype diversity. 
Apparently, phenotype differences between proband 219 and the rest of the affected family 2 
members might be caused by deviations in the COL1A1 gene expression or mRNA transport 
mechanisms. To clearify the effect of the mutation in the current family and the cause of an 
intrafamiliar variety, further collagen expression and mRNA splicing, metabolizing and 
transporting analysis are required. 
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2.4.2  Frameshift mutation c.1128delT (p.Gly377AlafsX164) in COL1A1 may cause 
OI of different phenotypes   
Exome sequencing in three probands of family 10 discovered c.1128delT (p.Gly377AlafsX164) 
frameshift mutation in exon 17 (triple helical domain of collagen I α1 chain) of the COL1A1 
gene. The mutation has been reported 7 times in OI database before, as a variant causing mild OI 
(Zhang et al., 2012; Roschger et al., 2008; Willing et al., 1996; etc).
2
 Probands of family 10 
were clinically diagnosed with OI types I, IV and III.  
The discovered frameshift mutation results in a PTC, followed by NMD, which is the most 
common cause of OI type I (Willing et al., 1996). A signal to NMD is the presence of special 
mRNA-binding exon-exon junction protein complexes, which are attached to mRNA after 
splicing. If, after the translation, the protein complex stays attached to the mRNA downstream of 
the stop codon, the ribosome was released before the stop codon preterminally, and the NMD 
mechanism is launched (Chang et al., 2007). NMD results in the COL1A1 null allele. The 
number of mutated transcripts of collagen I α1 in the nucleus and the cytoplasm is significantly 
decreased. It is likely that there are other mechanisms to provide nonsense mRNA decay for 
COL1A1 transcripts. The stretch of conserved amino acids indicates an important functional 
meaning of the mutation position for protein.  
As mentioned above, one of the common features of all OI type I cases, is elevated 
mineralization of ECM, regardless of the kind of mutation. ECM mineralization analysis might 
help in distinguishing of OI types of the family 10 members. The analysis of collagen expression 
levels might reveal the reasons of intrafamilial diversity of family 10. 
 
2.4.3  Novel c.2317G>T COL1A1 mutation causes severe life-threatening OI  
Parent-child trio sequencing revealed novel missense c.2317G>T mutation in proband 716 of 
family 10. The proband appeared to be an OI type II “survivor”. The mutation leads to 
p.Gly773Cys substitution in collagen I α1 chain, and is absent from the OI database. 
The Gly773 residue of the collagen I α1 chain is located at MLBR2 (amino acid residues 680-
830 of the α1 chain). The region is rich in α1β1/α2β1 integrin binding sites. Right next to 773 
site, there are MMP 1, 2 and 13 interaction domains, HSP47, COMP, discoidin domain receptor 
2 and fibronectin binding sites. The region also acts as a fibrillogenesis inhibition site and 
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binding site for secreted, acidic, rich in Cys proteins (SPARC) (Sweeney et al., 2008) 
(Supplementary Figure 2).  
The inability to bind HSP47 chaperone may result in procollagen early folding and severe OI, 
similar to OI caused by mutations in the SERPINH1 gene. The defect in binding of MMP1 could 
influence interstitial collagen catabolism, altering proteolysis of the defective collagen fibrils 
(Fields et al., 2013). The lack of MMP13 binding might result in defective collagen 
mineralization as enzyme restructures fibrils for proper mineralization (Johansson et al., 2000). 
Defective SPARC binding may cause problems in Ca
2+ 
binding with collagen (Yiu et al., 2001). 
The absence of integrin binding to collagen may cause the loss of interactions between cells and 
collagen so that ECM and cell binding, and osteoblast homeostasis would be interrupted, and the 
bone might gain fragility. The loss of fibronectin binding sites might affect fibril cross-linking 
(Kadler et al., 2008). As mentioned above, the region is crucially important for collagen 
interaction with NCP, fibril self-assembly, tissue mineralization, and ECM formation. In this 
way, the mutation in the MLBR2 region may simultaneously affect the tissue morphogenesis in 
diverse ways. However, the main load of the mutation effect must be provided on the fibril 
assembly since the function of the most binding NCPs of the MLBR2 region consists of 
fibrillogenesis. 
The MLBR2 region was reported as exclusively lethal (Marini et al., 2007), although the nearby 
regions contain residues where mutations may cause unlethal OI types I, IV, III (Sweeney et al., 
2008). Severity of the mutation effect depends - in addition to mutation position - on amino acid 
substitution. Two cases of c.2317G>A missense mutations causing p.Gly773Ser substitution 
have been described before (Marini et al., 2007; Chamberlain et al., 2004). Patients were 
diagnosed with OI type III. Gly substitutions with Ser and Cys are quite close to each other in 
degree of severity, as described previously. The key difference is bigger volume of Cys, in 
contrast to Ser and its ability to form disulfide bridges. Collagen fibril structure was altered more 
in the case of p.Gly773Cys mutation and might result in lethal phenotype. However, the patient 
survived until the age of 14 years, which indicates a transitional OI form between types II and 
III. OI type II survivor phenotype might have been determined not only by extreme care of the 
parents but also deviations in collagen expressivity or tissue mineralization that facilitated the 
effect of lethal mutation. Other reported cases of OI caused by missense mutations in the 
p.Gly773 position could shed light on lethality potential of the substitutions of the current amino 
acid residue. 
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CONCLUSION 
Osteogenesis Imperfecta is a group of hereditary disorders connected to bone brittleness and 
skeletal deformities. Phenotypes of the disorder differ with high variety ranging from mild OI 
type I, to moderate OI type IV, interosseous calcification OI type V, severe OI type III, and 
lethal OI type II.  
OI is caused by mutations in 16 different genes. About 90% of OI cases are represented by 
autosomal-dominant mutations in collagen I, which is the main structural part of the bone. Mild 
OI is usually caused by quantitative collagen defects, whereas severe OI is caused by qualitative 
collagen defects. 
In the current study exome analysis of three Estonian OI families was performed. All causative 
mutations were found in the COL1A1 gene, what supports the primary strategy of OI diagnosis, 
including priority screening of the COL1A1 and COL1A2 genes.  
Family 2 with an autosomal-dominant inheritance pattern of the disease showed segregation of 
the autosomal-dominant 5’canonical splice site mutation c.1821+1G>A. The mutation causes 
retention of intron 26 and defective mRNA transport to the cytoplasm. The deficient amount of 
collagen type I α1 chain mRNAs results in null-allele, collagen quantitative defect and mild OI 
type I, as the main part of the affected probands of family 2 did. However, one of the patients 
had a more severe phenotype, which correlated with OI type III. 
Exome analysis of family 10 discovered segregation of the autosomal dominant frameshift 
mutation c.1128delT (p.Gly377AlafsX164). The mutation results in mRNA decay and as a 
result, COL1A1 null-allele, collagen quantitative defect and mild OI phenotype. However, the 
probands revealed phenotypes of OI type I, IV, III. 
In family 7, novel  autosomal-dominant missense mutation c.2317G>T (p.Gly773Cys) was 
found. The mutation appeared in the MLBR2 region of the collagen I α1 chain, which is 
important for collagen interactions with NCPs and fibril self-assembly. The importance of the 
region is noted with the high number of reported lethal mutations. Current proband appeared to 
be an OI type II survivor. Obviously, the case studied is an in-between form of lethal and 
unlethal forms of OI, which indicated deficient OI classification and poor genotype-phenotype 
correlation concepts.  
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The results of the study give additional information about diversity of the disease genotypes and 
raise questions on intrafamilial diversity. Further studies of collagen expressivity have to be 
provided in families 2 and 10 in order to produce information about the causes of intrafamilial 
diversity. 
The results of exome analysis of family 7 give a new insight into lethality prediction and 
classification of the disease. Future reports about mutations at the same p.Gly773 residue will 
provide a decision on pathogenicity and genotype-phenotype correlations of the current 
mutation. The results of the study also confirm, that exome analysis is an effective method for OI 
causing mutation discovery. 
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Osteogenesis Imperfecta geneetiline eelsoodumus: eksoomi analüüs Eesti  
perekondades 
Lidiia Zhytnik 
RESÜMEE 
 
Osteogenesis Imperfecta (OI) ehk “habraste luude haigus” on geneetiline haigus, mille 
tüüpilisteks tunnusteks on sagedased luumurrud, skeleti deformatsioonid ning sinised silmad. OI 
teisteks enamlevinud sümptomiteks, mis võivad esineda on skolioos, vähenenud luude mass 
(osteoporoos või osteopeenia), Dentinogenesis Imperfecta (DI), kasvupeetus, liigeste lõtvus, 
kuulmislangus ja kolmnurkse kujuga nägu. Fenotüübid on individuaalsed ja sageli erinevad mitte 
ainult sama mutatsiooni kandjate vahel, vaid isegi ühe perekonna sees. OI on väga heterogeenne 
haigus, mis varieerub kergest osteopeeniast kuni perinataalselt letaalsuse vormini. Haiguse 
üldine esinemissagedus on umbes 1/20 000-30 000 sünnituse kohta ning esinemissagedus sõltub 
OI tüübist. Eestis on hetkel teada 32 OI perekonda, kellest enamikul esineb haigus läbi mitme 
põlvkonna. OI-d põhjustavad mutatsioonid 16 erinevates geenides. 85-90% juhtumitest tekkivad 
kollageeni I α1 ja α2 ahelate (COL1A1, COL1A2 geenid) mutatsioonide tõttu. 
Sillence’i klassifikatsiooni järgi eristatakse nelja klassikalist OI tüüpi.. I OI tüüp on tavaline 
kerge, mittedeformeeruv OI, mille peamiseks kliiniliseks tunnuseks on sinised skleerad. II OI 
tüüp on perinataalselt letaalne. Kolmas OI tüüp on raske progressiivselt deformeeruv OI. IV OI 
tüüp on varieeruv, milleraskusaste on mõõdukas. Viimasel ajal eristatakse ka V OI tüüpi, mille 
puhul esinevad teistest tüüpidest erinevad histoloogilised ja röntgenoloogilised muutused 
Tegemist on interosseuste membraanide kaltsifitseerimisega OI ja hüpertroofilise kallusega. 
Käesolevas töö on eesmärgiks oli teostada eksoomi sekveneerimisanalüüs kolmes eesti OI 
perekondades ja määrata OI-tekitavaid mutatsioone.  
Perekonnas 2 leiti AD päranduv 5’splaissaiti mutatsioon c.1821+1G>A, mis põhjustas  
kerget OI. Mutatsiooni tagajärjel lülitati sisse 26. intron kollageeni I α1 ahela mRNAsse. 
Defektne mRNA ei läbi tuuma SC-35 domääni kontrolli ja mRNA eksporti tsütoplasmasse ei 
toimu. Tulemuseks on haplopuudulikkus ja kollageeni kvantitatiivne defekt. Sekveneeritud 
patsientidel esines fenotüübi järgi I ja IV tüüpi OI.  
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Perekonnas 10 määrati AD päranduv c.1128delT (p.Gly377AlafsX164) raaminihke mutatsioon, 
mis põhjustas patsientidel erineva raskusastmega OI (tüübid I, IV, III). Antud mutatsioon 
põhjustab mRNAde lagundamist NMD kaudu ja haplopuudulikkust. Kvantitatiivne kollageeni 
defekt peaks avalduma kui kerge OI, aga fenotüübi varieeruvus perekonnas oli suurem. 
Perekonnas 7 esines de novo tekkinud OI mutatsiooni juhtum. Patsiendil esines II tüüpi OI ning 
ta suri 14,5-aastasena. Tal leiti uus, OI andmebaasist puuduv missense c.2317G>T 
(p.Gly773Cys) mutatsiooni, mis põhjustas eriti raske ja eluohtliku OI. Mutatsioon esines 
kollageeni I α1 ahela piirkonnas, mis vastutab ligandide seondumise eest. Tulemuseks on 
defektid, mis ilmnevad kollageeni ja fibrillide voltimises, mineralisatsiooni puudulikkuses, 
ekstratsellulaarmaatriksi kujunemise häires ja osteoblastide homeostaasis.  
Uuringu tulemused annavad lisainformatsiooni OI genotüüpide varieeruvusest, aga ei anna 
vastust perekonnasisese haiguse varieeruvuse kohta. Selleks on vajalikud täiendavad kollageeni 
ekspressiooni uuringud, luude mineralisatsiooni analüüs ning detailne mRNA analüüs 
perekondades 2 ja 10, mis aitaks selgitada perekonnasisese varieeruvuse põhjusi.  Perekonna 7 
eksoomi analüüsi tulemused annavad uut informatsiooni haiguse letaalsuse ennustamiseks. 
Järgnevad raportid c.2317G>T (p.Gly773Cys) mutatsiooni kandlusega OI juhtumitest annaksid 
uusi võimalusi hinnata OI letaalsuse ja mitte-letaalsuse suhteid antud positsioonis. Kokkuvõtteks 
võiks öelda, et eksoomi analüüs on efektiivne meetod uute OI variantide leidmiseks. 
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SUPPLEMENTARY DATA 
 
 
Figure 1 Collagen type I biosynthesis. Proteins involved into recessive OI are indicated in purple color 
(Shapiro et al., 2013). 
69 
 
 
Figure 2 Map of ligand binding site domains of collagen type I fibrils. The legend is represented below 
(Sweeney et al., 2008). 
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α1β1 integrin - α1β1 integrin binding sites 
α2β1 integrin - α2β1 integrin binding sites 
α11β1 integrin - α11β1 integrin binding sites 
AD - Mutation associated with arterial dissections 
ANE - Mutation associated with aneurysm 
CAD - Mutation associated with cervical artery dissections 
CAF - Mutation associated with Caffey Disease (Infantile cortical hyperstole) 
Col V X-link - Collagen V cross-link site 
COMP - Cartilage oligomeric matrix protein binding sites 
CPC - C-Proteinase cleavage site 
CTW - Mutation associated with connective tissue weakness 
DC integrin - Integrin binding site on denatured collagen 
DDR2 - Proposed site of discoidin domain receptor 2 binding 
Decorin - core Decorin core protein binding site 
DI - Mutations associated with Dentinogenesis Imperfecta 
[PS] DS PG - Proposed site of dermatan sulfate proteoglycan binding 
EDS - Mutations associated with Ehlers-Danlos Syndrome 
EDS7L - Mutations associated with Ehlers-Danlos VII-Like Syndrome 
ENDO180 - Collagen binding factor 
Fibril (+) - C-telopeptide fibrillogenesis nucleation domain 
Fibril (-) - Fibrillogenesis inhibition site 
Fibril (-) - 50%, 100% - 50 or 100% inhibition of fibrillogenesis by peptides 
G X - Substitution mutation 
GE-decorin - Guanidine-extracted decorin binding sites 
Glycation - Glycation sites 
HEP - Heparin, heparan sulfate proteoglycan binding site 
HSP47 - Potential heat shock protein 47(chaperone) binding sites 
ICA - Mutation associated with intracranial aneurysms 
[PS] KS PG - Proposed sites of keratan sulfate proteoglycan binding 
MFS - Mutation associated with Marfan Syndrome 
MMP-1 - Matrix Metalloproteinase-1 cleavage site 
MMP 1, 2, 13 -  1, 2, 13 
MMP Interaction Domain - Matrix Metalloproteinase Interaction Domain 
N-ANCHOR DOMAIN - Proposed N-anchor Domain 
NPC - N-Proteinase cleavage site 
OI - Mutations associated with Osteogenesis imperfecta 
types 1, 2, 3, 4; ?/US - denotes difficult diagnosis/unusual phenotype 
OPA - Mutation associated with Osteopaenia; ? denotes unusual phenotype 
OPO - Mutations associated with Osteoporosis; ? denotes unusual phenotype 
P-3-H - Site of Prolyl-3-hydroxylation 
PHOSPH - Phosphophoryn binding site 
SPARC - Secreted protein acidic and rich in cystein binding site 
THP/α1, 2, 11-β1 integrin - Triple helical peptide: binds integrin receptors 
THP/ANG- - Triple helical peptide: inhibits angiogenesis 
THP/ECA+ - Triple helical peptide: promotes endothelial cell activation 
THP/FA+; - Triple helical peptide: promotes fibroblast adhesion, substrate for MMPs 
THP/HB; ANG- - Triple helical peptide: binds heparin, inhibits angiogenesis 
THP/OBD - Triple helical peptide: supports osteoblastic differentiation 
μ - Unfolding Proposed Microunfolding domain 
VWF - Proposed Site of von Willebrand Factor binding 
X-LINK - Intermolecular cross-link site 
Orange - Cell interaction domain 
Yellow - Keratan sulfate proteoglycans binding region on the fibril 
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Blue - Glycation region on the fibril 
Green - Phosphophoryn binding region on the fibril 
Pink - Dermatan/chondroitin sulfate proteoglycans/decorin binding region on the fibril 
Black - Brackets Matrix interaction domain 
Red Brackets - Delineate clusters of lethal OI mutations on the α2(I) chain 
Blue Boxes - Regions containing 3 or more first position glycines on both chains where no human 
mutations have been reported. 
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